← Leaderboards
Roy M Gulick
Weill Medical Coll Of Cornell Univ
$56,577,103
Attributed
$56,577,103
Total exposure
21
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$56,577,103 · 21
By mechanism
UM1$41,085,976 · 1
U01$6,451,317 · 1
T32$4,613,613 · 1
M01$2,807,002 · 17
K24$1,619,195 · 1
Top collaborators
No co-investigators on record.
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Matteo Porotto$18,361,086
- Macarthur Charles$654,210
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchResearch PersonnelHiv InfectionsTrainingAnti-Retroviral AgentsClinical Trials UnitCommunitiesClinical Research SiteAreaResearch SupportHiv SeroprevalenceMentorsNew York CityAmericanClinical InvestigatorNeighborhoodsSeroprevalencesClinical TrialsLeadershipMedical SchoolsCommunicable DiseasesAids Clinical Trial GroupAids/Hiv ProblemAntiretroviral Therapy
Grant awards (70)
Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials Unit$3,611,304
UM1 · FY2025 · AI · contact PI
Research Training in Infectious Diseases$509,781
T32 · FY2025 · AI · contact PI
Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials Unit$3,238,675
UM1 · FY2024 · AI · contact PI
Research Training in Infectious Diseases$431,304
T32 · FY2024 · AI · contact PI
Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials Unit$3,235,110
UM1 · FY2023 · AI · contact PI
Research Training in Infectious Diseases$419,373
T32 · FY2023 · AI · contact PI
Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials Unit$3,694,380
UM1 · FY2022 · AI · contact PI
Research Training in Infectious Diseases$415,826
T32 · FY2022 · AI · contact PI
Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials Unit$4,582,651
UM1 · FY2021 · AI · contact PI
Research Training in Infectious Diseases$405,233
T32 · FY2021 · AI · contact PI
Weill Cornell Medical College-New Jersey Medical School Clinical Trials Unit$4,228,318
UM1 · FY2020 · AI · contact PI
Research Training in Infectious Diseases$414,358
T32 · FY2020 · AI · contact PI
WCM-Rutgers NJMS CTU Supplement for COVID Testing$300,000
UM1 · FY2020 · AI · contact PI
Weill Cornell Medical College-New Jersey Medical School Clinical Trials Unit$4,802,563
UM1 · FY2019 · AI · contact PI
Weill Cornell Medical College-New Jersey Medical School Clinical Trials Unit$2,067,523
UM1 · FY2018 · AI · contact PI
T32: Pathogenesis of Infectious Diseases Training Program$326,860
T32 · FY2018 · AI · contact PI
Weill Cornell Medical College-New Jersey Medical School Clinical Trials Unit$2,057,943
UM1 · FY2017 · AI · contact PI
T32: Pathogenesis of Infectious Diseases Training Program$355,476
T32 · FY2017 · AI · contact PI
Weill Cornell Medical College-New Jersey Medical School Clinical Trials Unit$2,108,745
UM1 · FY2016 · AI · contact PI
T32: Pathogenesis of Infectious Diseases Training Program$206,639
T32 · FY2016 · AI · contact PI
Weill Cornell Medical College-New Jersey Medical School Clinical Trials Unit$1,965,634
UM1 · FY2015 · AI · contact PI
T32: Pathogenesis of Infectious Diseases Training Program$357,155
T32 · FY2015 · AI · contact PI
Weill Cornell Medical College-New Jersey Medical School Clinical Trials Unit$2,456,647
UM1 · FY2014 · AI · contact PI
T32: Pathogenesis of Infectious Diseases Training Program$351,271
T32 · FY2014 · AI · contact PI
Cornell Clinical Trials Unit$1,273,956
UM1 · FY2013 · AI · contact PI
Pathogenesis of Infectious Diseases Training Program$420,337
T32 · FY2013 · AI · contact PI
Cornell Clinical Trials Unit$1,462,527
UM1 · FY2012 · AI · contact PI
Antiretroviral Therapy for HIV-Infected Patients$183,986
K24 · FY2012 · AI · contact PI
Cornell Clinical Trials Unit$1,227,503
U01 · FY2011 · AI · contact PI
Antiretroviral Therapy for HIV-Infected Patients$183,986
K24 · FY2011 · AI · contact PI
Cornell Clinical Trials Unit$1,371,244
U01 · FY2010 · AI · contact PI
Antiretroviral Therapy for HIV-Infected Patients$183,986
K24 · FY2010 · AI · contact PI
Cornell Clinical Trials Unit$180,651
U01 · FY2010 · AI · contact PI
Cornell Clinical Trials Unit$1,345,095
U01 · FY2009 · AI · contact PI
Antiretroviral Therapy for HIV-Infected Patients$183,986
K24 · FY2009 · AI · contact PI
Cornell Clinical Trials Unit$1,184,443
U01 · FY2008 · AI · contact PI
Antiretroviral Therapy for HIV-Infected Patients$183,986
K24 · FY2008 · AI · contact PI
Cornell Clinical Trials Unit$1,142,381
U01 · FY2007 · AI · contact PI
Antiretroviral Therapy for HIV-Infected Patients$140,514
K24 · FY2007 · AI · contact PI
A5001: ADULT AIDS CLINICAL TRIALS GROUP LONGITUDINAL LINKED RANDOMIZED TRIAL$41,061
M01 · FY2007 · RR · contact PI
A5202: A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR$39,222
M01 · FY2007 · RR · contact PI
A5211: PHASE II OF SCH417690, ORAL HIV-1 ENTRY INHIBITOR IN HIV$3,685
M01 · FY2007 · RR · contact PI
A5175: A PHASE IV, PROSPECTIVE, RANDOMIZED, OPEN-LABEL EVALUATION OF THE EFFICAC$1,582
M01 · FY2007 · RR · contact PI
ACTG 362:LONG-TERM ASSESSMENT FOR METABOLIC, CARDIOVASCULAR AND NEUROLOGIC COMP$1,313
M01 · FY2007 · RR · contact PI
A5142/PH III/LOPINAVIR/RITONAVIR+EFAVIR FOR INITIAL THERAPY OF HIV-1 INFECTION$261
M01 · FY2007 · RR · contact PI
A5001: ADULT AIDS CLINICAL TRIALS GROUP LONGITUDINAL LINKED RANDOMIZED TRIAL$345,068
M01 · FY2006 · RR · contact PI
A5211: PHASE II OF SCH417690, ORAL HIV-1 ENTRY INHIBITOR IN HIV$232,546
M01 · FY2006 · RR · contact PI
A5142/PH III/LOPINAVIR/RITONAVIR+EFAVIR FOR INITIAL THERAPY OF HIV-1 INFECTION$167,531
M01 · FY2006 · RR · contact PI
Antiretroviral Therapy for HIV-Infected Patients$140,514
K24 · FY2006 · AI · contact PI
A5202: A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR$122,522
M01 · FY2006 · RR · contact PI
A5095: PHASE III, RANDOMIZED, DOUBLE-BLIND COMPARISON OF THREE PI-SPARING$5,011
M01 · FY2006 · RR · contact PI
A5175: A PHASE IV, PROSPECTIVE, RANDOMIZED, OPEN-LABEL EVALUATION OF THE EFFICAC$2,498
M01 · FY2006 · RR · contact PI
A5001: ADULT AIDS CLINICAL TRIALS GROUP LONGITUDINAL LINKED RANDOMIZED TRIAL$209,064
M01 · FY2005 · RR
A5095: PHASE III, RANDOMIZED, DOUBLE-BLIND COMPARISON OF THREE PI-SPARING$155,811
M01 · FY2005 · RR
A5142/PH III/LOPINAVIR/RITONAVIR+EFAVIR FOR INITIAL THERAPY OF HIV-1 INFECTION$145,954
M01 · FY2005 · RR
Antiretroviral Therapy for HIV-Infected Patients$140,514
K24 · FY2005 · AI
A5211: PHASE II OF SCH417690, ORAL HIV-1 ENTRY INHIBITOR IN HIV$55,223
M01 · FY2005 · RR
A5118- A RANDOMIZED PHASE I/II PLACEBO-CONTROLLED STUDY OF AMDOXOVIR (DAPD)$21,697
M01 · FY2005 · RR
ACTG 362:LONG-TERM ASSESSMENT FOR METABOLIC, CARDIOVASCULAR AND NEUROLOGIC COMP$13,804
M01 · FY2005 · RR
A5143: A RANDOMIZED, COMPARATIVE STUDY OF LOPINAVIR/RITONAVIR VS GW433908 VS$3,947
M01 · FY2005 · RR
INTENSIVE PHARMACOKINETIC STUDY OF LOPINAVIR/RITONAVIR AND GW433908$1,977
M01 · FY2005 · RR
A5095: PHASE III, RANDOMIZED, DOUBLE-BLIND COMPARISON OF THREE PI-SPARING$350,325
M01 · FY2004 · RR
A5142/PH III/LOPINAVIR/RITONAVIR+EFAVIR FOR INITIAL THERAPY OF HIV-1 INFECTION$283,807
M01 · FY2004 · RR
A5118- A RANDOMIZED PHASE I/II PLACEBO-CONTROLLED STUDY OF AMDOXOVIR (DAPD)$217,288
M01 · FY2004 · RR
A5001: ADULT AIDS CLINICAL TRIALS GROUP LONGITUDINAL LINKED RANDOMIZED TRIAL$208,428
M01 · FY2004 · RR
Antiretroviral Therapy for HIV-Infected Patients$140,514
K24 · FY2004 · AI
INTENSIVE PHARMACOKINETIC STUDY OF LOPINAVIR/RITONAVIR AND GW433908$97,556
M01 · FY2004 · RR
A5143: A RANDOMIZED, COMPARATIVE STUDY OF LOPINAVIR/RITONAVIR VS. GW433908 VS$48,784
M01 · FY2004 · RR
ACTG 362:LONG-TERM ASSESSMENT FOR METABOLIC, CARDIOVASCULAR AND NEUROLOGIC COMP$31,037
M01 · FY2004 · RR
Antiretroviral Therapy for HIV-Infected Patients$137,209
K24 · FY2003 · AI